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Abstract: 
Objective: High-resolution peripheral quantitative computed tomography (HR-pQCT) 
has potential to improve radiographic progression determination in clinical trials and 
longitudinal observational studies. The goal of this work is to describe the current state 
of research presented at OMERACT 2016, and ensuing future directions outlined during 
discussion among attendees.  
 
Methods: At OMERACT 2016, SPECTRA introduced efforts to (i) validate HR-pQCT 
according to OMERACT guidelines - focusing on in rheumatoid arthritis (RA), and (ii) 
alternatives for automated joint space width (JSW) analysis. The SIG was presented to 
patient research partners, physicians/researchers and SIG leaders followed by a 40-
minute discussion on future directions. 
 
Results: A consensus definition for RA erosion using HR-pQCT was demonstrated 
through a systematic literature review and a Delphi exercise.  Histopathology and 
perfusion studies were presented which explore the true nature of cortical breaks in HR-
pQCT images, and provide Criterion Validity. Results indicate readers are able to 
discriminate between erosion and small vascular channels. Moderate reliability (ICC: 
0.206-0.871) of direct erosion size measures was shown, which improves (>0.9) when 
only experienced readers are considered. Quantification of erosion size was presented for 
scoring, direct measurement and volumetric approaches, as well as a reliability exercise 
for direct measurement. Three methods for JSW measurement were compared, all 
indicating excellent reproducibility with differences at the extremes (i.e. near-zero and 
joint edge thickness).  
 
Conclusion: Initial reports on HR-pQCT are promising, however to consider its use in 
clinical trials and longitudinal observational studies, it is imperative to assess the 
responsiveness of erosion measurement quantification.  
 
 
Key Indexing Terms (MeSH): X-Ray Computed Tomography; 3-D Imaging; Arthritis, 
Rheumatoid; Metacarpophalangeal Joint; OMERACT 
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INTRODUCTION 
Radiographic progression is a key outcome in randomized controlled trials for 
inflammatory arthritis. Unfortunately, the power of this assessment is limited in the early 
diagnosis and treat-to-target paradigm in RA, with most patients demonstrating little 
baseline joint damage or progression during trials. This is compounded with early timing 
of rescue therapies and limited exposure durations. In observational studies, plain 
radiography is the most feasible method for assessing damage progression, but only 
provides a 2D evaluation of a 3D surface, resulting in errors related to positioning and 
overlapping bony interfaces. Current radiographic scoring schemes are based on ordinal 
scoring of joint space width (JSW) and erosions, predisposing results to floor and ceiling 
effects, and significant progression is required to reach the incremental worsening 
threshold to detect score progression. For these reasons diagnostic imaging biomarkers 
with higher sensitivity to change, such as high-resolution peripheral quantitative 
computed tomography (HR-pQCT), could improve radiographic progression 
determination in clinical trials and longitudinal observational studies, as well as adding 
new outcomes for detection of pre-erosive bony changes (1), quantification of joint space 
narrowing, and assessment of bone densitometry and microarchitecture (2).  
 
HR-pQCT is a relatively young imaging modality for quantitative evaluation of cortical and 
trabecular bone mineral density and bone microstructure, typically at the distal radius 
and tibia (3, 4). Quantitative measurements obtained with HR-pQCT are well established 
as biomarkers and outcome measures in osteoporosis research (5). HR-pQCT uses a very 
low irradiation dose (<5 µSv to image a 1 cm region of interest) and is approved by the US 
Food and Drug Administration. There are 70-75 sites worldwide, distributed on all 
continents, using either 82 or 60 Pm isotropic resolution technology (SCANCO Medical 
AG, Brüttisellen, Switzerland). Advantages of HR-pQCT adoption in peripheral small joint 
imaging include high resolution, and detection of periarticular bone damage such as 
erosions, cysts, joint space narrowing and bone proliferations in inflammatory and 
degenerative disease not visualized sensitively with other imaging technologies such as 
plain radiography, ultrasound and magnetic resonance imaging (6, 7). 
 
Pilot studies in inflammatory arthritis conditions demonstrated that scanning protocols 
were well tolerated by patients with active inflammation and those with chronic joint 
changes. Because motion artefact is a concern in image acquisition, scanning protocols 
were developed, along with position holders to stabilize the area of interest. Patient 
positioning and image acquisition takes 5-10 minutes compared to other imaging 
modalities such as conventional CT (10-15 Minutes) or MRI (20-45 minutes). Costs for 
one measurement by HR-pQCT varies between countries, but are comparable to a 
standard bone densitometry (DEXA) scan. 
 
From this early pilot work, independent labs began to test the application of HR-pQCT for 
imaging peripheral joints. Some initial publications described visible pathological 
manifestations (6), while others compared findings at different stages of rheumatoid 
arthritis (8, 9) as well as different types of inflammatory arthritis, degenerative arthritis, 
and normal states (10, 11). Since then, 44 individual studies using HR-pQCT for arthritis 
assessment have been published or presented as abstracts (12), and led to the 
involvement of the SPECTRA collaboration in the formal OMERACT validation process. 
The collaboration is a global network of rheumatologists, clinicians, epidemiologists, 
engineers, radiologists, fellows, students, physicists, paediatricians, and industry 
partners. The inaugural SPECTRA meeting in Calgary in 2011 focused on standardizing 
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image acquisition across centres (13). Since then, membership has grown to 20 
investigative sites from 5 continents, demonstrating clear interest in applying this 
technology in arthritis assessment for clinical research. The principal aims of SPECTRA 
are to (i) investigate HR-pQCT for arthritis assessment in clinical trials, (ii) validate HR-ǯ
process, and (iii) harmonizǯ.  
 
SPECTRA adheres to the OMERACT filter 1.0 incremental validation process - truth, 
feasibility, discrimination, and filter 2.0, pathophysiological manifestations (14). The goal 
has been to target evaluation for findings sensitive to change in biologically relevant 
intervals not captured by current imaging techniques, and improve the correlation of 
imaging findings to function, which is significantly delayed with existing technologies.  
The aim of this work is to describe the current state of research as presented at OMERACT 
2016, and the ensuing future directions outlined during the discussion among attendees. 
 
 
MATERIALS AND METHODS: 
At OMERACT 2016 in Whistler, Canada in May 2016, SPECTRA introduced HR-pQCT as a 
new imaging modality for outcome measures in clinical trials and longitudinal       
 ȋ
ȌǤ  ǯ current 
research in validating HR-pQCT according to OMERACT guidelines was presented, 
focusing on the definition and evaluation of erosion in RA, and an automated algorithm 
for JSW analysis.  
The SIG was presented to patient research partners, physicians/researchers and SIG 
leaders at OMERACT 2016. Following a 20-minute presentation, a 40-minute discussion 
on important next steps and future directions was moderated by two SIG leaders, with 
the other two SIG leaders collecting minutes.  
 
RESULTS: 
The SPECTRA SIG at OMERACT 2016 was attended by two patient research partners, 16 
physicians/researchers and four SIG leaders.  
 
Current State of Research 
Pathophysiological Manifestations Visible with HR-pQCT 
Table 1 shows current and ongoing research efforts presented at the SIG, as well as future 
research directions allowing conformity to OMERACT guidelines. 
 
1. Definition and evaluation of erosions in RA 
A consensus definition for RA erosions visualized by HR-pQCT was deemed an essential 
first step towards development of measurement frameworks. A systematic literature 
review was presented, and identified multiple approaches for defining erosion in HR-
pQCT images (8, 15-17). These are consistent in that a cortical break must be present, and 
was expanded to assert that the break must be visible over multiple slices and in multiple 
planes. Erosion shape definition was also important (18), and differentiation between 
erosions and vessel channels was deemed necessary, Figure 1.  
 
Eleven readers reviewed the definition and performed two scoring exercises to further 
refine it. A final scoring exercise on 58 joints gave 90% agreement on erosion presence, 
kappa 0.52 (95%CI 0.37-0.63) for all readers (of varying experience), and for experienced 
readers, kappa 0.76 (19).         ?ǯ
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experience. These results were presented to 11 separate investigators and a Delphi 
exercise was performed. Results indicated 100% acceptance of the proposed definition. 
 
A histopathology study was presented, which explores the true nature of cortical breaks 
in HR-pQCT (Criterion Validity), and provides anatomic data supporting the SPECTRA 
definition. A perfusion study with barium sulphate was presented, which correlates linear 
cortical channels with penetrating blood vessels (20). This data confirms the SPECTRA 
definition of erosion and that HR-pQCT can distinguish bone erosion from small vascular 
channels; a critical distinction for discrimination between healthy controls and 
individuals with early RA, who exhibit both physiologic vascular channels and small bone 
erosions (20). 
 
Multiple approaches to measure erosion have been identified (21) Ȃ using either a semi-
quantitative score, a direct measurement from 2D images, or volumetric approximation. 
Given that volumetric methods are not widely available, results from direct measurement 
were presented. Consensus was reached on a standard approach, which was tested for 
reliability in the RELEX-1 reading exercise. Moderate reliability was obtained 
(perpendicular width RMSCV 12.3%, ICC 0.206; axial width RMSCV 20.6%, ICC 0.665; 
perpendicular depth RMSCV 24.0%, ICC 0.783; axial depth RMSCV 22.2%, ICC 0.871) (19). 
ICCs increased to >0.9 for experienced readers only. Plans for a second study investigating 
responsiveness of the direct measurement approach (RELEX-2), as well as automated 
quantitative strategies consistent with the SPECTRA definition were described. 
 
2. Joint Space Width 
JSW is an indirect measure of arthritis disease activity. A systematic literature review was 
presented which identified published approaches to joint space measurement (15, 22, 
23). Specifically, three techniques for high-throughput, robust, reproducible, fully-
automated, quantitative 3D measurements of JSW from HR-pQCT derived data have been 
published (15, 22, 23). 
 
In order to standardise JSW measurement among the SPECTRA consortium, a study has 
been performed to reach consensus on one method; either one of the three published or 
a hybrid. The methods were compared to test JSW measurement reliability (i) across a 
spectrum of RA disease (early to late), (ii) in scan/rescan (including re-positioning), and 
(iii) for the same joints measured on the two HR-pQCT devices available commercially 
(XtremeCT and XtremeCT II, Scanco Medical AG). Results indicate excellent 
reproducibility, with all three methods able to discriminate JSW across a spectrum of 
disease, and mean and minimum JSW estimates comparable between them. This 
comparison revealed that maximum JSW estimates were significantly different between 
the three methods, while minimum JSW reliability was sensitive to scan/rescan errors, 
particularly in joints with substantial narrowing, due to differences in handling zones 
with zero or near-zero thickness, Figure 2. There was no difference in JSW when 
measured using the two models of HR-pQCT. 
 
DISCUSSION: 
SIG Discussion & Future Research Directions  
Following presentation of current research, future research directions were discussed. A 
consensus emerged that it is now imperative to perform a longitudinal study assessing 
the responsiveness of erosion measurement quantification, where one scoring method, 
direct measurement or automated measurement, must be selected which gives reliable 
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estimates of change over time and with treatment. If a manual method is selected, 
calibration of readers is required. Consequently, identification of disease specific cut-offs 
in erosion and JSW metrics, compared to normal findings in healthy controls, is necessary.  
Furthermore, it was recommended that performance of HR-pQCT be tested for detecting 
and quantifying pathological manifestations in comparison to other modalities (e.g. 
ultrasound, MRI) (18, 21), as well as other rheumatological diseases; e.g. osteoarthritis, 
psoriasis and psoriatic arthritis, and crystal arthropathies. Translation of the methods to 
other sites of interest, for example the wrist (23) or metatarsophalangeal joints, would 
also aid in increasing sensitivity to detect activity in site-specific diseases.  
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Figure Legends 
 
Figure 1. HR-pQCT image of the metacarpophalangeal head, transverse view. Arrows 
indicate examples of (a) an erosion and (b) a vessel channel.  
 
Figure 2. (a) and (b) Two examples of HR-pQCT images of the MCP II joint at different 
stages of arthritis disease, and (c) and (d) their corresponding joint space masks. 
Colours indicate where each of the three algorithms (1, 2, 3) had full (white), partial 
(orange, purple, green) or no agreement (yellow, red, blue) in defining the joint space 
mask volume. Joint space volume for (a) was 90, 94 and 70 mm3, and (b) 106, 114, 87 
mm3, for algorithms 1, 2 and 3, respectively. 
 
